BSH 2017 | What does the CLL forum data tell us?
George Follows, MA, BM, BCh, PhD, FRCP, FRCPath, from Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK discusses the Chronic Lymphocytic Leukemia (CLL) forum data and the outcome of patients treated with ibrutinib. The collation of long-term data and subsequent analysis has revealed that the rate of patients discontinuing ibrutinib is slowing down however, patients discontinuing due to progressive CLL is increasing with time. For this cohort, second-line therapy of venetoclax indicates better survival outcomes. Dr Follows also discusses the long-term effects of treatment breaks on patient outcomes, and the effect of dose reduction. This interview was recorded at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
